drugset / Trial / NCT07368478
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ia/Ib, open-label, dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, and preliminary anticancer activity of BC2027 in patients with advanced solid Malignanciesr
Timeline
- Start
- 2025-11-24
- Primary completion
- 2027-12
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC2027 | Unknown | 0.8 mg/kg | Intravenous |
| Subject | BC2027 | Unknown | 1.2 mg/kg | Intravenous |
| Subject | BC2027 | Unknown | 1.8 mg/kg | Intravenous |
| Subject | BC2027 | Unknown | 2.4 mg/kg | Intravenous |